My research identifies factors at the patient, provider, health system, and policy levels that can be modified to improve access to and receipt of affordable cancer prevention, screening, treatment, survivorship, and end-of-life care. The underlying goals of this research are to reduce disparities and improve equity in cancer outcomes.”
As Scientific Vice President, Health Services Research, Surveillance & Health Equity Science, Robin Yabroff, PhD, MBA, leads a team of scientists whose research focuses on:
The effects of health policies, including provisions of the Affordable Care Act, on access to cancer prevention, screening, survivorship, and end-of-life care
As an expert in these areas, Yabroff is a frequent speaker at national and international meetings and a participant of panels and think tanks.
She holds adjunct faculty positions in the Department of Medicine at Johns Hopkins University and in the Department of Health Policy and Management at Emory University’s Rollins School of Public Health.
Yabroff has received multiple National Institutes of Health Merit Awards for her research leadership and mentorship. She led the development of the Medical Expenditure Panel Survey (MEPS): Experiences with Cancer Survivorship Supplement from 2009 to 2015. The goal of this multi-institutional, collaborative effort was to improve the quality of publicly available data for estimating the burden of cancer in the United States.
She is a founding member of the Interagency Consortium to Promote Health Economics Research on Cancer (HEROiC).
To learn more about Yabroff's work, listen to the podcast “Preventing Financial Hardship from Cancer.”
Yabroff has co-authored over 300 peer-reviewed journal articles, invited editorials, commentaries, and book chapters.
She has on-going editorial roles for several journals, including:
Yabroff has been a guest editor for the:
She has also been a featured guest on the Journal of Clinical Oncology (JCO) podcast.
For a complete list of Dr. Yabroff’s publications, see her Google Scholar page.
If this was helpful, donate to help fund patient support services, research, and cancer content updates.